Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine

Tuberculosis Clinical Trial

Official title:

A Randomized, Open Clinical Trial Phase 1 Vaccine TB/FLU-01L by Intranasal and Sublingual Application for Specific Immunotherapy Pulmonary Tuberculosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03017378
• Other study ID #: VIT-I-01/2013
• Status: Completed
• Phase: Phase 1
• First received: January 4, 2017
• Last updated: January 10, 2017
• Start date: October 2013
• Est. completion date: February 2015

Study information

• Verified date: January 2017
• Source: Research Institute for Biological Safety Problems
• Contact: n/a
• Is FDA regulated: No
• Health authority: Kazakhstan: National Center for Expertise of Drugs, Medical Products and Equipment
• Study type: Interventional

Clinical Trial Summary

The study is a single centre, phase I, open, randomized, by intranasal and sublingual application trial that explored the safety and immunogenicity of 2 doses (Day 1 and Day 21) TB/FLU-01L tuberculosis vaccine in BCG-vaccinated healthy adult subjects aged 18-50 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: February 2015
• Est. primary completion date: April 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Healthy BCG-vaccinated male or female adult 18 through 50 years of age at the enrollment visit.

• Literate and willing to provide written informed consent.

• A signed informed consent.

• Capable and willing to complete diary cards and willing to return for all follow-up visits.

• For females, willing to take reliable birth control measures throughout the entire period of participation in the study

Exclusion Criteria:

• Clinical, radiological (chest X-ray) or laboratory evidence of active or past TB disease.

• Current or past administration of anti-TB therapy.

• History of contact with TB patients.

• Positive QuantiFERON-TB Gold test.

• BCG vaccination in less than 6 months prior to study.

• Practice of nasal irrigation on a regular basis within the past six months or has engaged in nasal irrigation within two weeks prior to enrollment.

• Recent history of frequent nose bleeds (>5 within the past year).

• Clinically relevant abnormal paranasal anatomy.

• Recent history (within the past month) of rhino or sinus surgery, or surgery for any traumatic injury of the nose.

• Current or recent (within two weeks of enrollment) acute respiratory illness with or without fever.

• Hypersensitivity after previous administration of any vaccine.

• History of chronic alcohol abuse and/or illegal drug use.

• Any clinically significant abnormal laboratory finding.

• A positive pregnancy test for all women of childbearing potential.

• Administration of immunosuppressive drugs or other immune modifying drugs within 4 weeks prior to study enrollment.

• Acute or chronic clinically significant pulmonary disease, cardiovascular disease, gastrointestinal disease, liver disease, neurological illness, liver disease, blood disease, skin disorder, endocrine disorder, neurological illness and psychiatric disorder as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives.

• History of leukemia or any other blood or solid organ cancer.

• Seropositive for HIV, hepatitis B surface antigen and/or hepatitis C antibodies.

• Receipt of antivirals, antibiotics, immunoglobulins or other blood products within 4 weeks prior to study enrollment or planned receipt of such products during the period of subject participation in the study.

• Participation in another clinical trial within the previous three months or planned enrollment in such a trial during the period of this study.

• Subjects who are, in the opinion of the investigator, at significantly increased risk of non-cooperation with requirements of the study protocol.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Biological:
• TB/FLU-01L
TB / FLU-01L (intranasal application)
• TB/FLU-01L
TB/FLU-01L (sublingual application)

Locations

Country	Name	City	State
Kazakhstan	National Center for Tuberculosis Problems, Kazakhstan	Almaty Qalasy	Almaty

Sponsors (3)

Lead Sponsor	Collaborator
Research Institute for Biological Safety Problems	National Center for Tuberculosis Problems, Kazakhstan, Research Institute of Influenza, Russia

Country where clinical trial is conducted

Kazakhstan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events (AE) - Immediate reactions	Commonly Solicited Local reactions associated with injections: pain, erythema/redness, swelling, induration, bruising at the injection site.	Two hours	Yes
Primary	Solicited local and systemic reactions	Commonly Solicited general symptoms: fever (oral temperature = 38.0°C), chills, muscle aches/myalgia, arthralgia, fatigue, malaise, headache, rash, sweating, nausea, vomiting, diarrhea and potential indicators of oculo-respiratory syndrome* (ORS).	Greater than 2 hours after administration of any dose of vaccine through 7 days following any dose	Yes
Primary	Unsolicited AEs	Unsolicited AEs are any untoward medical occurrence in the subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product	Greater than 2 hours after administration of any dose of vaccine or placebo through 7 days following any dose	Yes
Primary	Serious adverse events (SAEs), including abnormal laboratory findings	Serious adverse events (SAEs) are medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.	Three weeks of receipt of any dose	Yes